2025 China Adenovirus Vector Vaccine Market Revenue Opportunities Report
Description
The 2025 China Adenovirus Vector Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adenovirus Vector Vaccine Market in China are CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd. (BIOKANGTAI), AIM Vaccine, and Walvax Biotechnology.
CanSino Biologics Inc. is a leading Chinese vaccine company specializing in adenovirus-based viral vector technology. It has developed several adenovirus vector vaccines, including Convidecia (COVID-19 vaccine) and Ad5-EBOV (Ebola vaccine), with large-scale manufacturing bases in Tianjin and Shanghai. CanSino has also expanded global distribution through local partnerships in Mexico, Pakistan, and Malaysia.
Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) has a licensing agreement with AstraZeneca to manufacture and commercialize the recombinant COVID-19 adenovirus vector vaccine within China as well as overseas markets like Pakistan and Indonesia. BIOKANGTAI has expanded production capacity to address vaccine shortages and contribute to global vaccine equity.
AIM Vaccine is a prominent vaccine manufacturer in China with a strong R&D and production pipeline, including adenovirus vector-based COVID-19 vaccines. The company has multiple wholly owned manufacturing affiliates and is engaged in developing innovative vaccines with rapid clinical progress and expansion plans within China.
Walvax Biotechnology has developed a chimpanzee adenovirus vector COVID-19 vaccine candidate currently in clinical trials. Walvax is building manufacturing capacity for vaccine production with plans to produce over 200 million doses annually to supply domestic and international demand.
Together, these companies play critical roles in advancing adenovirus vector vaccine technology, expanding production capacity, and supporting both domestic immunization and global vaccine accessibility from China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vector Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Adenovirus Vector Vaccine Market in China are CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd. (BIOKANGTAI), AIM Vaccine, and Walvax Biotechnology.
CanSino Biologics Inc. is a leading Chinese vaccine company specializing in adenovirus-based viral vector technology. It has developed several adenovirus vector vaccines, including Convidecia (COVID-19 vaccine) and Ad5-EBOV (Ebola vaccine), with large-scale manufacturing bases in Tianjin and Shanghai. CanSino has also expanded global distribution through local partnerships in Mexico, Pakistan, and Malaysia.
Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) has a licensing agreement with AstraZeneca to manufacture and commercialize the recombinant COVID-19 adenovirus vector vaccine within China as well as overseas markets like Pakistan and Indonesia. BIOKANGTAI has expanded production capacity to address vaccine shortages and contribute to global vaccine equity.
AIM Vaccine is a prominent vaccine manufacturer in China with a strong R&D and production pipeline, including adenovirus vector-based COVID-19 vaccines. The company has multiple wholly owned manufacturing affiliates and is engaged in developing innovative vaccines with rapid clinical progress and expansion plans within China.
Walvax Biotechnology has developed a chimpanzee adenovirus vector COVID-19 vaccine candidate currently in clinical trials. Walvax is building manufacturing capacity for vaccine production with plans to produce over 200 million doses annually to supply domestic and international demand.
Together, these companies play critical roles in advancing adenovirus vector vaccine technology, expanding production capacity, and supporting both domestic immunization and global vaccine accessibility from China.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
